Economic Evaluation of Rituximab + Recombinant Human Thrombopoietin vs. Rituximab for the Treatment of Second-Line Idiopathic Thrombocytopenic Purpura in China

Economic Evaluation of Rituximab + Recombinant Human Thrombopoietin vs. Rituximab for the Treatment of Second-Line Idiopathic Thrombocytopenic Purpura in China

Objective: This study aimed to compare the economic evaluation of recombinant human thrombopoietin+rituximab (rhTPO + RTX) vs. RTX as second-line treatment for adult patients with immunologic thrombocytopenic purpura in China.Methods: The Markov model was used in our research. The response rate and...

Full description

Bibliographic Details
Main Authors: Mingjun Rui, Yingcheng Wang, Zhengyang Fei, Ye Shang, Aixia Ma, Hongchao Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Medicine
Subjects:
cost-effectiveness (CE)
immunologic thrombocytopenic purpura
rituximab
RhTPO
Markov model
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.657539/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2021.657539/full

Similar Items